We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Idera Pharmaceuticals Announces Selection of Toll-like Receptor (TLR) Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck

News   Jan 11, 2012

 
Idera Pharmaceuticals Announces Selection of Toll-like Receptor (TLR) Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck
 
 
Advertisement
 

RELATED ARTICLES

Four-Stranded DNA Plays a Role in Certain Types of Breast Cancer

News

Four stranded DNA structures called G-quadruplexes have been shown to play a role in certain types of breast cancer, providing a potential new therapeutic target.

READ MORE

Altering Roundworm Proteins To Develop Anti-Aging Drugs

News

Researchers have been able to alter creatures’ lifespans by altering the activity of proteins found in roundworm cells that tell them to convert sugar into energy when their cellular energy is running low. Humans also have these proteins, offering up intriguing possibilities for developing longevity-promoting drugs.

READ MORE

Head and Neck Cancer: Mutant HRAS Is a Key Cancer-Driving Oncogene

News

Researchers report that an investigational drug called tipifarnib shows promise in treating head and neck squamous cell carcinoma tumors with mutations in the HRAS gene.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE